First-line natalizumab in multiple sclerosis: Rationale, patient selection, benefits and risks

Therapeutic Advances in Chronic Disease

Volumn 5, Issue 2, 2014, Pages 62-68

  Nicholas, Jacqueline Ann ^a   Racke, Michael Karl ^a   Imitola, Jamie ^a   Boster, Aaron Lee ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

JC polyomavirus; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy; Treatment algorithm

Indexed keywords

NATALIZUMAB; PLACEBO;

ALGORITHM; DISEASE ACTIVITY; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84898911579     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622313514790     Document Type: Review

References (31)

1. Berger J. (2011) The pathogenesis of progressive multifocal leukoencephalopathy. Discovery Med 12: 495–503.
2. Berger J. Houff S. Gurwell J. Vega N. Miller C. Danaher R. (2013) JC virus antibody status underestimates infection rates. Ann Neurol 74: 84–90.
3. Berger J. Koralnik I. (2005) Progressive multifocal leukoencephalopathy and natalizumab–unforeseen consequences. N Engl J Med 353: 414–416.
4. Biogen Idec (2013) PML incidence in patients receiving Tysabri® (natalizumab). Available at: https://medinfo.biogenidec.com
5. Bloomgren G. Richman S. Hotermans C. Subramanyam M. Goelz S. Natarajan A. et al. (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366: 1870–1880.
6. Borriello G. Prosperini L. Mancinelli C. Gianni C. Fubelli F. Pozzilli C. (2012) Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol 19: 783–787.
7. Clifford D. de Luca A. Simpson D. Arendt G. Giovannoni G. Nath A. (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9: 438–446.
8. Cree B. Al-Sabbagh A. Bennett R. Goodin D. (2005) Response to interferon β-1a treatment in African American multiple sclerosis patients. Arch Neurol 62: 1681–1683.
9. Cree B. Khan O. Bourdette D. Goodin D. Cohen J. Marrie R. et al. (2004) Clinical characteristics of African Americans vs. Caucasian Americans with multiple sclerosis. Neurology 63: 2039–2045.
10. Cree B. Reich D. Khan O. de Jager P. Nakashima I. Takahashi T. et al. (2009) Modification of multiple sclerosis phenotypes by African ancestry at HLA. Arch Neurol 66: 226–233.
11. Cree B. Stuart W. Tornatore C. Jeffery D. Pace A. Cha C. (2011) Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. Arch Neurol 68: 464–468.
12. Dong-Si T. Richman S. Bloomgren G. Wenten M. Philip G. Datta S. et al. (2013) Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis patients: survival and functional outcome when asymptomatic at diagnosis. 65th Annual Meeting of the American Academy of Neurology, San Diego, CA.
13. Gorelik L. Lerner M. Bixler S. Crossman M. Schlain B. Simon K. et al. (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68: 295–303.
14. Havrdova E. Galetta S. Hutchinson M. Stefoski D. Bates D. Polman C. et al. (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) Study. Lancet Neurol 8: 254–260.
15. Hutchinson M. Kappos L. Calabresi P. Confavreux C. Giovannoni G. Galetta S. et al. (2009) The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 256: 405–415.
16. Kappos L. Butzkueven H. Pellegrini F. Trojano M. Wiendl H. Zhang A. Hotermans C. (2012) Long-term safety and efficacy and association between baseline treatment history and postbaseline relapses in multiple sclerosis patients treated with natalizumab in the TYSABRI® Observational Program (TOP). Neurology 78(Meeting Abstracts 1): P04.134.
17. Kaufman M. Johnson S. Moyer D. Bivens J. Norton H. (2003) Multiple sclerosis: severity and progression rate in african Americans compared with whites. Am J Phys Med Rehabil 82: 582–590.
18. Kleinschmidt-Demasters B. Tyler K. (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N Engl J Med 353: 369–374.
19. Langer-Gould A. Atlas S. Green A. Bollen A. Pelletier D. (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353: 375–381.
20. Lassmann H. Bruck W. Lucchinetti C.F. (2007) The immunopathology of Multiple Sclerosis: An Overview. Brain Pathol 17 (2): 210–218.
21. Magraner M. Coret F. Navarre A. Bosca I. Simo M. Escutia M. et al. (2011) Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol 258: 1805–1811.
22. McFarland H. Jacobson S. (2006) Natalizumab and immune cells. Arch Neurol 63: 1366–1367.
23. Plavina T. Bloomgren G. Richman S. Pace A. Lee S. Schlain B. et al. (2013) Anti-JCV antibody index further defines PML risk in natalizumab-treated MS patients. 27th Annual Meeting of the Consortium of Multiple Sclerosis Centers, Orlando, FL.
24. Polman C. O'Connor P. Havrdova E. Hutchinson M. Kappos L. Miller D. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910.
25. Rice G. Hartung H. Calabresi P. (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64: 1336–1342.
26. Rudick R. Stuart W. Calabresi P. Confavreux C. Galetta S. Radue E. et al. (2006) Natalizumab plus interferon β-1a for relapsing multiple sclerosis. N Engl J Med 354: 911–923.
27. Sargento-Freitas J. Batista S. Macario C. Matias F. Sousa L. (2013) Clinical predictors of an optimal response to natalizumab in multiple sclerosis. J Clin Neurosci 20: 659–662.
28. Sheremata W.A. Minager A. Alexander J.S. Vollmer T. (2005) The role of alpha-4 integrin in the aetiology of multiple sclerosis: Current knowledge and therapeutic implications. CNS Drugs 19 (11): 909–22.
29. Steinman L. (2005) Blocking Adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 4: 510–518.
30. Stuve O. Marra C. Jerome K. Cook L. Cravens P. Cepok S. et al. (2006) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59: 743–747.
31. van Assche G. van Ranst M. Sciot R. Dubois B. Vermeire S. Noman M. et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362–368.